Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Revolution Medicines, Inc. (RVMD)
Price$210.02Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M | $43.0M | $50.0M | $20.2M |
| Research & development | $987.3M | $592.2M | $423.1M | $253.1M | $186.9M | $132.3M | $91.8M | $51.1M |
| Operating expenses | $1.18B | $689.5M | $498.8M | $293.7M | $217.4M | $153.7M | $104.2M | $60.5M |
| Operating income | −$1.18B | −$689.5M | −$487.2M | −$258.3M | −$188.0M | −$110.7M | −$54.1M | −$40.3M |
| Operating margin | — | — | −4,207.12% | −730.01% | −639.70% | −257.54% | −108.15% | −200.00% |
| EBITDA | −$1.17B | −$683.0M | −$482.1M | −$254.3M | −$184.9M | −$108.1M | −$51.8M | −$38.8M |
| EBITDA margin | — | — | −4,163.58% | −718.79% | −629.21% | −251.46% | −103.61% | −192.23% |
| Net income | −$1.13B | −$600.1M | −$436.4M | −$248.7M | −$187.1M | −$108.2M | −$47.7M | −$41.8M |
| Net profit margin | — | — | −3,768.28% | −702.95% | −636.58% | −251.63% | −95.25% | −207.24% |
| Basic EPSper basic share | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | -$22.33 | -$21.24 |
| Diluted EPSper diluted share | -$5.95 | -$3.58 | -$3.86 | -$3.08 | -$2.57 | -$2.01 | -$22.33 | -$21.24 |
Owners
Reported shareholders
6.39%of listed shares
BlackRock, Inc.13.7M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 6.39%13.7M shares |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 6.32%13.55M shares |
FMR LLC | 5.69%12.2M shares |
BAKER BROS. ADVISORS LP | 5.34%11.44M shares |
Jupiter Topco LLC | 5.01%10.74M shares |
Darwin Global Management, Ltd. | 4.96%10.63M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.24%9.09M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.87%8.29M shares |
Nextech Invest Ltd. | 3.55%7.6M shares |
Schroeder Thilo | ≈3.55%7.6M shares |
Paradigm Biocapital Advisors LP | 2.97%6.36M shares |
UBS Group AG | 2.54%5.45M shares |
STATE STREET CORP | 2.29%4.9M shares |
Capital World Investors | 1.87%4.01M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.84%3.94M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.79%3.84M shares |
JPMORGAN CHASE & CO | 1.54%3.3M shares |
BVF INC/IL | 1.38%2.97M shares |
Alphabet Inc. | 1.38%2.95M shares |
Casdin Capital, LLC | 1.20%2.58M shares |
Percentages use 214.24M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Anders JackChief Financial Officer | SellCommon Stock | 300 | $170.32 | $51.1K | 123.3K |
| Jun 24, 2026Form 4 · 10b5-1 | Anders JackChief Financial Officer | SellCommon Stock | 5.7K | $169.24 | $956.4K | 123.6K |
| Jun 24, 2026Form 4 · 10b5-1 | Anders JackChief Financial Officer | SellCommon Stock | 9.5K | $168.20 | $1.60M | 129.2K |
| Jun 24, 2026Form 4 · 10b5-1 | Anders JackChief Financial Officer | SellCommon Stock | 4.6K | $167.35 | $761.9K | 138.7K |
| Jun 17, 2026Form 4 · 10b5-1 | Horn Margaret AChief Operating Officer | SellCommon Stock | 29.6K | $160.12 | $4.74M | 154.6K |